“哇！对于我们的广泛期小细胞肺癌患者来说，这是重大消息！” — @lungoncdoc
#DeLLphi305 #ESMO26：tarlatamab + durva 对比 durva，1L 维持治疗 ES-SCLC：OS 21.1 对比 12.7 个月（HR 0.42）。尚属研究性治疗。
@Amgen @AstraZeneca @BalazsHalmosMD
https://hubs.ly/Q04CdDQ00
21 浏览 · 0 赞 · 0 转发 · 0 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：KOL Pulse AI · x.com